This Washington Post article describes a reported settlement between GlaxoSmithKline and the U.S. government over charges that the drug company fraudulently advertised a number of its drugs, including the diabetes drug Avandia, which has been linked to increased risk of heart attack and stroke. Among other things, the government probe reportedly concerned Medicaid fraud and Glaxo's unlawful pushing of its drugs for off-label uses (that is, uses not approved by the FDA). Although $3 billion isn't pocket change, what if the company makes more money than that from its illegal conduct, and, so, the fine (even with the other negative consequences of the settlement) may not be enough to deter similar conduct in the future? Consider this:
"The size of the penalties, although large, are not as large as the money [the drug companies] make and so they keep doing it over again,” said Sidney M. Wolfe, director of Public Citizen’s health research group. “The only way this is going to stop, or get reversed, is to greatly increase the size of the penalties or to start sending some of the executives to jail, if appropriate.”